Table 1 |
|||||||||
|
Several individual markers are differentially methylated between the prognostic groups and neuroblastoma risk factors |
|||||||||
|
Type |
Subtype |
KRT19 |
FAS |
PRPH |
CNR1 |
QPCT |
HIST1H3C |
ACSS3 |
GRB10 |
|
|
|||||||||
|
Prognostic group |
LR-SURV |
0/31 (0%) |
1/31 (3%) |
14/31 (45%) |
2/31 (6%) |
18/31 (58%) |
0/31 (0%) |
0/31 (0%) |
6/31 (19%) |
|
HR-SURV |
14/30 (48%) |
8/30 (27%) |
24/30 (80%) |
10/30 (33%) |
25/30 (83%) |
2/30 (7%) |
14/30 (47%) |
13/30 (43%) |
|
|
HR-DOD |
9/28 (32%) |
6/28 (21%) |
19/28 (68%) |
10/28 (36%) |
24/28 (86%) |
6/28 (21%) |
7/28 (25%) |
11/28 (39%) |
|
|
Stage |
Stage 1 |
0/21 (0%) |
0/21 (0%) |
8/21 (38%) |
1/21 (5%) |
13/21 (62%) |
0/21 (0%) |
0/21 (0%) |
4/21 (19%) |
|
Stage 2 |
1/12 (8%) |
2/12 (17%) |
8/12 (67%) |
2/12 (17%) |
8/12 (67%) |
0/12 (0%) |
1/12 (8%) |
3/12 (25%) |
|
|
Stage 3 |
9/17 (53%) |
4/17 (24%) |
13/17 (77%) |
9/17 (53%) |
15/17 (88%) |
3/17 (18%) |
9/17 (58%) |
8/17 (47%) |
|
|
Stage 4 |
13/39 (33%) |
9/39 (15%) |
28/39 (72%) |
10/39 (26%) |
31/39 (80%) |
5/39 (18%) |
11/39 (28%) |
15/39 (39%) |
|
|
MYCN |
MYCN single copy |
7/50 (14%) |
2/50 (4%) |
24/50 (48%) |
5/50 (10%) |
31/50 (62%) |
0/50 (0%) |
2/50 (4%) |
14/50 (28%) |
|
MYCN amplified |
16/39 (41%) |
13/39 (33%) |
33/39 (85%) |
17/39 (44%) |
36/39 (92%) |
8/39 (21%) |
19/39 (49%) |
16/39 (41%) |
|
|
Age |
Age at diagnosis > 12 months |
21/53 (40%) |
14/53 (26%) |
37/53 (69%) |
18/53 (34%) |
46/53 (87%) |
8/53 (15%) |
21/53 (40%) |
24/53 (45%) |
|
Age at diagnosis < 12 months |
2/36 (6%) |
1/36 (3%) |
20/396(56%) |
4/36 (11%) |
21/36 (58%) |
0/36 (0%) |
0/36 (0%) |
6/36 (17%) |
|
|
Age at diagnosis > 18 months |
20/45 (44%) |
13/45 (29%) |
33/45 (73%) |
17/45 (38%) |
40/45 (89%) |
8/45 (18%) |
19/45 (49%) |
23/45 (51%) |
|
|
Age at diagnosis < 18 months |
3/44 (7%) |
2/44 (5%) |
24/44 (55%) |
5/44 (11%) |
27/44 (61%) |
0/44 (0%) |
2/44 (5%) |
7/44 (16%) |
|
|
Overall total |
23/89 (26%) |
15/89 (17%) |
57/89 (64%) |
22/89 (25%) |
67/89 (75%) |
8/89 (9%) |
21/89 (24%) |
30/89 (34%) |
|
|
Statistics (Fisher's exact P-value) |
|||||||||
|
Prognostic group |
<0.001 |
0.151 |
0.112 |
0.068 |
0.165 |
0.0624 |
<0.001 |
0.405 |
|
|
MYCN |
0.0594 |
0.008 |
0.008 |
0.008 |
0.017 |
0.0146 |
<0.001 |
0.708 |
|
|
Stage |
0.007 |
0.287 |
0.221 |
0.059 |
0.683 |
0.448 |
0.008 |
0.700 |
|
|
Age cutoff 12 months |
0.008 |
0.045 |
0.579 |
0.138 |
0.059 |
0.123 |
<0.001 |
0.059 |
|
|
Age cutoff 18 months |
0.002 |
0.045 |
0.326 |
0.059 |
0.045 |
0.0594 |
0.0015 |
0.012 |
|
|
|
|||||||||
|
The number (percentage) of methylated samples in each stratum is given. P-values according to the Fisher's exact test, corrected for multiple testing (Benjamini-Hochberg). HR-DOD, high-risk deceased patients; HR-SURV, high-risk patients alive for at least 1,000 days follow-up; LR-SURV, low-risk patients alive for at least 1,000 days follow-up. P-values in bold indicate significant associations. |
|||||||||
|
Decock et al. Genome Biology 2012 13:R95 doi:10.1186/gb-2012-13-10-r95 |
|||||||||
